HLTH VanEck Global Hlthcr Ldrs ETF
- 10.800
- +0.090+0.84%
Stocks Most Shunned by Hedge Funds and Mutual Funds
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
Liquidia Surges After United Therapeutics Request for Preliminary Injunction Denied
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 8.86%. Currently, Amgen has a market capitalization of $161
Analyst Expectations For Vertex Pharmaceuticals's Future
During the last three months, 10 analysts shared their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX), revealing diverse outlooks from bullish to bearish.
Buy Ideas in Managed Care and Healthcare Facilities - Baird
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $500
BMO Capital analyst Evan Seigerman maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $480 to $500.
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 12.65% BMO Capital $480 → $500 Maintains Outperform 05/07/2024 -4.47% RBC Capital $417 → $424 M
Why Sarepta Therapeutics Stock Is Rising Today
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.What Happened: Effective prior to the opening of tra
BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
Analyst Expectations For Tenet Healthcare's Future
Throughout the last three months, 14 analysts have evaluated Tenet Healthcare (NYSE:THC), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings
Baird Initiates Coverage On Tenet Healthcare With Outperform Rating, Announces Price Target of $153
Baird analyst Michael Ha initiates coverage on Tenet Healthcare (NYSE:THC) with a Outperform rating and announces Price Target of $153.
Tenet Healthcare Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 16.31% Baird → $153 Initiates Coverage On → Outperform 05/02/2024 11.74% Barclays $113 → $147 M
Are diet pills about to peak in the short term? This cartoon's predictions are probably more accurate than analysts
① In the US stock investment community, a saying called the “South Park” curse has been quietly circulating until now: any stock name that appears in the cartoon “South Park” will be sold off soon after; ② Now, the “South Park” spell has descended on the concept of diet pills.
NSSOL, Asahi, etc. (added) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|--------------|--------------|<4578＞|Otsuka HD |JPM | “Neutral” | “Over W” |Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |-----
Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]
○ List of sales conversion stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜1379＞ Hokuto 1822 1863 ＜1852＞ Asanuma Gumi 3600 3750 ＜1890＞ Toyoken 1386 1417 ＜2222＞ Kotobuki Spirits 1698 1826 ＜2305＞ Studio Alice 2003 2054
Sarepta Therapeutics To Join S&P Midcap 400, Effective June 3
Sarepta Therapeutics will replace Shockwave Medical in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson is acquiring Shockwave Medi
Here's How Much $1000 Invested In Encompass Health 15 Years Ago Would Be Worth Today
Encompass Health (NYSE:EHC) has outperformed the market over the past 15 years by 2.8% on an annualized basis producing an average annual return of 14.93%. Currently, Encompass Health has a market cap
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc's (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases.